AME

Business profile & competitive position

AME is AMETEK, Inc., an Industrials company in the Electrical Equipment & Parts industry. It operates through two segments: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). EIG makes advanced analytical, test and measurement instruments for the process, aerospace, power and industrial markets, while EMG supplies precision motion control solutions, highly engineered medical components and devices, thermal management systems, specialty metals and electrical interconnects to aerospace and defense, medical, automation and other industrial markets.

AMETEK’s real margin and return figures support the idea that it occupies a relatively defensible niche in industrial components. The company’s net margin stands at 20.0%, which is high for a diversified manufacturer of physical equipment, and its return on equity is 14.5%. Those numbers suggest AMETEK can price its specialized instrumentation and engineered components above its input costs and convert equity capital into profit at a respectable rate. For context, in fiscal 2025 AMETEK recorded sales of $7,401.1 million, up 6.6% from 2024, and diluted earnings per share of $6.40, up 7.9%. The company also reported record operating income, net income, orders and backlog that year. With approximately 22,500 employees and a multi-country manufacturing footprint, AMETEK’s scale and specialization appear to be the core of its competitive position rather than a single consumer brand or network effect.

Financial posture

AMETEK’s current market capitalization is $54.7 billion, and it trades at a trailing P/E of 34.7. That multiple sits at a premium to many industrial manufacturers, so the valuation is pricing in continued above-average profitability. Net margin of 20.0% and ROE of 14.5% explain some of that premium: the market typically assigns higher multiples to industrial businesses that combine steady margins with capital-efficient returns. Beta is 0.99, meaning the stock has shown volatility roughly in line with the overall market.

A recent valuation headline adds context without settling the debate. On September 16, 2026, GuruFocus published “Is AME Overvalued? DCF Says Worth $158,” a figure well below the current price of $238.525. Whether that discounted-cash-flow estimate proves accurate is outside this summary; the headline itself is simply one external data point that investors are using to frame the stock’s valuation.

Strategic priorities & outlook

AMETEK’s most recent 10-K filing outlines four operational priorities. The first is executing the AMETEK Growth Model, which targets high-single-digit annual sales growth, double-digit annual EPS growth, strong cash flow generation and a superior return on total capital. The second is operational excellence through lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, digitalization and artificial intelligence.

The third priority is acquisitions. From 2021 through December 31, 2025, AMETEK completed 15 acquisitions with roughly $1.8 billion in annualized sales. In 2025 alone, it spent $933.2 million in cash—net of cash acquired—to buy Kern, a provider of high-precision machining and optical inspection solutions, and FARO Technologies, a 3D measurement and imaging solutions company. The fourth priority is expanding globally and in emerging markets, supported by best-cost manufacturing facilities in China, Czechia, Malaysia, Mexico and Serbia intended for customer proximity and international growth.

Macro & geopolitical exposure

Because AMETEK sits in the Electrical Equipment & Parts industry, its exposures are those common to industrial component suppliers with global customers. International revenue is material: in 2025, 52% of EIG’s net sales and 42% of EMG’s net sales went to customers outside the United States. That foreign footprint creates currency translation exposure and makes tariff, trade-policy and cross-border supply-chain developments relevant.

The industry is also tied to commodity and component inputs—metals, semiconductors and engineered materials—so changes in raw-material costs, freight rates and availability can move margins. Aerospace and defense is a meaningful end market, implying sensitivity to defense budgets and procurement timing, while medical-device exposure brings regulatory and product-cycle considerations. Finally, industrial capital spending, interest rates and acquisition financing conditions all matter for a company whose growth model depends on both organic demand and bolt-on M&A.

Recent developments

Recent headlines have centered on valuation, ownership changes and post-earnings price action rather than operational disruptions:

• On September 17, 2026, Fool.com ran “NASA's New Moon Base Contract Could Be an Out-of-This-World Opportunity for This Under-the-Radar Nuclear Power Stock,” highlighting AMETEK as a possible beneficiary of aerospace and nuclear-related spending.
• On September 16, 2026, GuruFocus asked “Is AME Overvalued? DCF Says Worth $158,” flagging valuation skepticism.
• On September 4, 2026, Seeking Alpha’s “Baron SMID Cap ETF Q2 2026 Portfolio Activity” noted AMETEK among the ETF’s portfolio moves.
• On September 3, 2026, Zacks published “Why Is Ametek (AME) Down 8.5% Since Last Earnings Report?,” documenting a pullback since the August 4, 2026 release.

The current price is $238.525, with an RSI of 49.3 and the 50-day EMA at $238.87—effectively flat against that moving average. The next scheduled earnings date is October 29, 2026 before the market open, with a consensus EPS estimate of $2.11.

Earnings behavior & post-earnings drift

AMETEK has delivered an unusually consistent earnings track record. Over the last eight reported quarters, the company beat the consensus estimate eight times out of eight, for a 100% beat rate, with an average earnings surprise of 4%. The average 5-day price move in the five trading days following earnings across those quarters was just 0.46%, classified as “flat.” In other words, the market has steadily underestimated AMETEK, yet the stock has not consistently drifted higher after the beats.

The four most recent quarters illustrate the mixed post-earnings reaction:

• August 4, 2026: actual EPS of $2.09 versus an estimate of $1.99, a 5.0% surprise; the stock rose 0.28% the next day and 0.89% over the following five days.
• April 30, 2026: actual EPS of $1.97 versus an estimate of $1.90, a 3.7% surprise; the stock fell 2.13% the next day and 0.33% over the following five days.
• February 3, 2026: actual EPS of $2.01 versus an estimate of $1.94, a 3.6% surprise; the stock fell 0.48% the next day but gained 1.83% over the following five days.
• October 30, 2025: actual EPS of $1.89 versus an estimate of $1.76, a 7.4% surprise; the stock rose 1.91% the next day and then declined 0.54% over the following five days.

Heading into the October 29, 2026 report, the official consensus EPS estimate is $2.11. The historical pattern suggests the market’s real expectation may be somewhat above that printed number, but the post-report price reaction has been directionally unpredictable.

For a deeper dive beyond these data points, consider reviewing the full institutional verdict on AME—including sell-side ratings, price-target dispersion and recent ownership changes—before forming your own view.